Palonosetron Sala

Palonosetron, the active ingredient in Palonosetron Sala, is a 5‑HT3 receptor antagonist presented as a strength/form for intravenous use. It is used to prevent nausea and vomiting associated with chemotherapy and surgery in adult patients. GNH USA supplies Palonosetron Sala as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

GNH USA supplies Palonosetron Sala as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Palonosetron is a selective 5‑HT3 receptor antagonist used in the management of chemotherapy‑induced and postoperative nausea and vomiting.

- Chemotherapy‑induced nausea and vomiting (CINV): helps prevent acute and delayed episodes in patients receiving highly emetogenic chemotherapy. - Post‑operative nausea and vomiting (PONV): reduces the incidence of nausea and vomiting after general anesthesia. - Radiotherapy‑induced nausea and vomiting: provides prophylaxis when radiotherapy involves the abdomen or pelvis. - Antiemetic prophylaxis for pregnancy‑related hyperemesis: used off‑label in some regions for severe nausea when other treatments fail.

Palonosetron is generally well tolerated, but adverse reactions have been reported.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: occasional bowel movement changes. - Fatigue: feeling of tiredness without exertion. - Dizziness: transient light‑headed sensations. - Injection site erythema: mild redness at the administration site.

Serious or Rare Side Effects: - Allergic reaction: rash, itching, swelling, or anaphylaxis. - Cardiac arrhythmia: QT interval prolongation in susceptible individuals. - Severe constipation or intestinal obstruction. - Serotonin syndrome: rare when combined with other serotonergic agents. - Hypotension: notable drop in blood pressure post‑administration.

Palonosetron should be used with consideration of patient‑specific factors and proper handling.

- Cardiac assessment: evaluate QT interval in patients with known cardiac disease. - Concomitant serotonergic drugs: avoid or monitor for serotonin syndrome. - Renal impairment: adjust use in severe renal dysfunction. - Pregnancy and lactation: use only if clearly needed; discuss risks with a healthcare professional. - Storage: Store below 25°C: keep in the original pack, protect from moisture.

Palonosetron may interact with other medications that affect cardiac rhythm or serotonin pathways.

Major Interactions (Avoid): - Drugs that prolong QT interval: may increase risk of cardiac arrhythmias. - Strong CYP3A4 inhibitors: can raise palonosetron plasma levels.

Moderate Interactions (Monitor Closely): - Serotonergic agents (e.g., SSRIs, SNRIs, triptans): monitor for serotonin syndrome. - Anticholinergic medications: may enhance constipation risk. - Diuretics: watch for additive blood pressure effects. - Antihistamines: may alter perceived efficacy of anti‑emetic therapy.